RPPA: Origins, Transition to a Validated Clinical Research Tool, and Next Generations of the Technology

Emanuel Petricoin 3rd; Julie Wulfkuhle; Marissa Howard; Marielena Pierobon; Virginia Espina; Alessandra Luchini; Lance A Liotta

doi:10.1007/978-981-32-9755-5_1

RPPA: Origins, Transition to a Validated Clinical Research Tool, and Next Generations of the Technology

Adv Exp Med Biol. 2019:1188:1-19. doi: 10.1007/978-981-32-9755-5_1.

Authors

Emanuel Petricoin 3rd¹, Julie Wulfkuhle¹, Marissa Howard¹, Marielena Pierobon¹, Virginia Espina¹, Alessandra Luchini¹, Lance A Liotta²

Affiliations

¹ Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA.
² Center for Applied Proteomics and Molecular Medicine, George Mason University, Manassas, VA, USA. [email protected].

PMID: 31820380
DOI: 10.1007/978-981-32-9755-5_1

Abstract

RPPA technology has graduated from a research tool to an essential component of clinical drug discovery research and personalized medicine. Next generations of RPPA technology will be a single clinical instrument that integrates all the steps of the workflow.

Keywords: Biomarkers; Drug discovery; Integrative genomics; RPPA; Reverse-phase protein array; Technology.

MeSH terms

Precision Medicine* / instrumentation
Precision Medicine* / trends
Protein Array Analysis* / standards
Protein Array Analysis* / trends
Proteomics*
Research / instrumentation
Research / trends